Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
Surprise Trump tariff pause erases weekly smallcap losses. What’s in store going ahead?
Indian markets ended positive after US paused reciprocal tariffs, easing investor concerns. Smallcaps recovered late, while IT, metals, and capital goods rallied. Focus now shifts
April 12, 2025